Zentalis Pharmaceuticals, Inc. (ZNTL) has a consensus analyst rating of Buy, based on 12 analysts covering the stock. Of those, 8 recommend buying, 4 recommend holding, and 0 recommend selling.
The analyst consensus price target for ZNTL is $2.00, representing a -62.7% downside from the current price of $5.36. Price targets range from a low of $2.00 to a high of $2.00.
